Rx License-Rx

TAB-181

NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of inflammatory disease, and their anti-inflammatory effects are believed to result from their ability to inhibit the formation of prostaglandins by prostaglandin H synthase (COX). Two forms of prostaglandin H have been identified, COX-1 and COX-2. The former seems to be constitutively expressed in a variety of tissues while the high expression of the latter has been reported in colorectal tumors. NSAIDs have been shown to be effective in reducing human colorectal cancers and possibly breast and lung cancers. While the exact mechanism(s) by which NSAIDs function has not been elucidated, they could potentially play a critical role in detecting, diagnosing and treating inflammatory diseases as well as cancer. The present invention relates to screening methods for the identification of agonistic and/or antagonistic agents for the activation of the promoter...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Lung cancer

Modality: Small Molecule

Focus tags: Oncology, Inflammation

Technology tags: Small Molecule, Diagnostic / Biomarker

Mechanism:

Development stage: Early / Discovery

Patent status: Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with National Institutes of Health. The practical first use case is Lung cancer. Public description: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of inflammatory disease, and their anti-inflammatory effects are believed to result from their ability to inhibit the formation of prostaglandins by.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Lung cancer

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Best next experiment: Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.